Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.41 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.41 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | AKT1 | P31749 | 1/20 | 0.38 |
| ▸ | EGFR | P00533 | 1/20 | 0.38 |
| ▸ | SCN1A | P35498 | 1/20 | 0.37 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.37 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30736662 | 1.00 | ALDH1A1 (0.45) | ALDH1A1LMNAADRA1AADRA1BKCNA5 | |
| SCHEMBL10433539 | 0.87 | KCNA5 (0.47) | ALDH1A1LMNAADRA1AADRA1BKCNA5 | |
| SCHEMBL5476839 | 0.87 | ALDH1A1 (0.46) | ALDH1A1LMNAADRA1AADRA1BKCNA5 | |
| SCHEMBL951581 | 0.86 | TSHR (0.46) | ALDH1A1LMNAADRA1AADRA1BTSHR | |
| SCHEMBL7675373 | 0.84 | ALDH1A1 (0.42) | ALDH1A1LMNAADRA1AADRA1BKCNA5 | |
| SCHEMBL3499475 | 0.84 | LMNA (0.44) | ALDH1A1LMNAADRA1AADRA1BKCNA5 | |
| SCHEMBL28626456 | 0.84 | PDK1 (0.36) | ALDH1A1LMNAADRA1AADRA1BKCNA5 | |
| SCHEMBL15000886 | 0.84 | MRGPRX4 (0.39) | ALDH1A1LMNAADRA1AADRA1BKCNA5 | |
| SCHEMBL30000533 | 0.84 | PDK1 (0.36) | ALDH1A1LMNAADRA1AADRA1BKCNA5 | |
| SCHEMBL18481771 | 0.83 | ALDH1A1 (0.45) | ALDH1A1LMNAADRA1AADRA1BKCNA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260034123-A1 | CDK2 INHIBITORS AND METHODS OF USING THE SAME | CEDILLA THERAPEUTICS INC (US) | 2026-02-05 | — | — | US | disclosed |
| EP-4561575-A2 | CDK2 INHIBITORS AND METHODS OF USING THE SAME | Cedilla Therapeutics, Inc. (US) | 2025-06-04 | — | — | EP | disclosed |
| EP-4562016-A2 | CDK2 INHIBITORS AND METHODS OF USING THE SAME | Cedilla Therapeutics, Inc. (US) | 2025-06-04 | — | — | EP | disclosed |
| US-20250066367-A1 | Pyrimidine-Annulated Triazole Derivatives and Their Use in Platelet Aggregation Inhibition | BEIJING HONGHUI MEDITECH CO., LTD (CN) | 2025-02-27 | — | — | US | disclosed |
| WO-2024026486-A2 | CDK2 INHIBITORS AND METHODS OF USING THE SAME | CEDILLA THERAPEUTICS, INC. (US) | 2024-02-01 | — | — | WO | disclosed |
| WO-2024026483-A2 | CDK2 INHIBITORS AND METHODS OF USING THE SAME | CEDILLA THERAPEUTICS, INC. (US) | 2024-02-01 | — | — | WO | disclosed |
| WO-2024026483-A2 | CDK2 INHIBITORS AND METHODS OF USING THE SAME | CEDILLA THERAPEUTICS, INC. (US) | 2024-02-01 | — | — | WO | disclosed |
| CN-111051298-B | 3- (1-oxo-isoindolin-2-yl) piperidine-2, 6-dione derivative and application thereof | 诺华股份有限公司 | 2023-06-27 | — | — | CN | disclosed |
| CN-112119082-A | Pyrrolobenzodiazepines and conjugates thereof | 免疫医疗有限公司 | 2020-12-22 | — | — | CN | disclosed |
| EP-3138841-A1 | D2 ANTAGONISTS, METHODS OF SYNTHESIS AND METHODS OF USE | Altos Therapeutics, LLC (US) | 2017-03-08 | — | — | EP | disclosed |
| US-20140179743-A1 | NON-ATP DEPENDENT INHIBITORS OF EXTRACELLULAR SIGNAL-REGULATED KINASE (ERK) | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2014-06-26 | — | — | US | disclosed |
| EP-2582701-A1 | D2 ANTAGONISTS, METHODS OF SYNTHESIS AND METHODS OF USE | Altos Therapeutics, LLC (US) | 2013-04-24 | — | — | EP | disclosed |
| US-20120010228-A1 | D2 ANTAGONISTS, METHODS OF SYNTHESIS AND METHODS OF USE | Altos Therapeutics, LLC | 2012-01-12 | — | — | US | disclosed |
| WO-2011160084-A1 | D2 ANTAGONISTS, METHODS OF SYNTHESIS AND METHODS OF USE | Altos Therapeutics, LLC (US) | 2011-12-22 | — | — | WO | disclosed |
| EP-1663936-B1 | BIARYLOXYMETHYLARENE-CARBOXYLIC ACIDS | HOFFMANN LA ROCHE (CH) | 2008-01-09 | — | — | EP | disclosed |
| US-20070275995-A1 | Thiobenzimidazole derivatives | TEIJIN PHARMA LIMITED | 2007-11-29 | — | — | US | disclosed |
| US-7268145-B2 | Thiobenzimidazole derivatives | TEIJIN PHARMA LIMITED (JP) | 2007-09-11 | — | — | US | disclosed |
| US-20060040976-A1 | Thiobenzimidazole derivatives | TEIJIN LIMITED | 2006-02-23 | — | — | US | disclosed |
| US-20050267148-A1 | Benzimidazole derivative | TEIJIN LIMITED | 2005-12-01 | — | — | US | disclosed |
| EP-1097926-A1 | THIOBENZIMIDAZOLE DERIVATIVES | TEIJIN LIMITED (JP) | 2001-05-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260034123-A1 | CDK2 INHIBITORS AND METHODS OF USING THE SAME | CDK2, CDK1, CDK20 | ALDH1A1 4103/4885LMNA 1665/4885ADRA1A 3866/4885 |
| US-20070275995-A1 | Thiobenzimidazole derivatives | CMA1, SERPINB1, TMPRSS15 | ALDH1A1 466/4885LMNA 4278/4885ADRA1A 2337/4885 |
| US-20250066367-A1 | Pyrimidine-Annulated Triazole Derivatives and Their Use in Platelet Aggregation Inhibition | P2RY12, P2RY11, P2RY13 | ALDH1A1 916/4885LMNA 4380/4885ADRA1A 725/4885 |
| US-20140179743-A1 | NON-ATP DEPENDENT INHIBITORS OF EXTRACELLULAR SIGNAL-REGULATED KINASE (ERK) | MAPK1, MAP3K1, MAP3K20 | ALDH1A1 1499/4885LMNA 3633/4885ADRA1A 687/4885 |
| US-20060040976-A1 | Thiobenzimidazole derivatives | CMA1, SERPINB1, TMPRSS15 | ALDH1A1 466/4885LMNA 4278/4885ADRA1A 2337/4885 |
| US-20050267148-A1 | Benzimidazole derivative | CMA1, SERPINB1, TPSAB1 | ALDH1A1 264/4885LMNA 3900/4885ADRA1A 2482/4885 |
| US-20120010228-A1 | D2 ANTAGONISTS, METHODS OF SYNTHESIS AND METHODS OF USE | DRD2, DRD3, AVPR2 | ALDH1A1 873/4885LMNA 4596/4885ADRA1A 57/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.